Theme 1 TCR
Antonio Bertoletti, MD is an expert in the field of viral hepatitis. He began working in viral hepatitis as a medical student at the University of Parma (Italy). During his MD specialization (1991) in Infectious Diseases he spent two years at The Scripps Research Institute (La Jolla) characterizing for the first time in human the Hepatitis B virus (HBV) specific cytotoxic T cells. He returned to the University of Parma, where he worked in the Department of Infectious Diseases as a Clinical Scientist continuing his study of human HBV specific T cells (1991-1997). before joining “The UCL Institute of Hepatology” at University College of London (UK) (1997).
In 2006 he moved to Singapore where he was the Director of Infection and Immunity Program at the Singapore Institute for Clinical Sciences (A*STAR) until 2013 before moving at the Emerging Infectious Disease Program at Duke-NUS Medical School. In 2015, he co-founded (with Dr Li Lietao) Lion TCR pte, a biotech company developing new immune based treatment for virus-related cancers (HBV-HCC and EBV related malignancies) and chronic viral infections.
Immunopathogenesis of HBV infection. His current research is focus on understanding the impact of age in HBV infection/pathology and on the development of new immunological based therapies (TCR-redirected T cells) for the treatment of HBV and Hepatocellularcarcinoma